SS Innovations International (NASDAQ: SSII) has announced record second-quarter 2026 revenue of $13.9 million, a 39.4% increase from $10 million in the same period last year, signaling robust demand for its SSi Mantra surgical robotic system. The company's installations of the system rose 30.4% to 30 during the quarter, contributing to a cumulative installed base of 224 systems across 12 countries as of June 30.
The financial results, detailed in the company's press release, show gross profit increased 20% to $7.1 million, with a gross margin of 50.9%. Despite a net loss of $2.7 million, or $0.01 per diluted share, compared to a net loss of $0.3 million a year earlier, the company's first-half revenue surged 65.6% to $25 million, with installations up 47.4% to 56.
This growth is particularly significant as SS Innovations continues to expand its global footprint and advance its regulatory strategy. The company expects the U.S. Food and Drug Administration (FDA) to complete its review of the SSi Mantra's 510(k) premarket notification by the end of the first quarter of 2027. Additionally, it believes it can secure European Union CE marking certification by the end of 2026. These milestones are critical for entering major markets and could unlock substantial growth opportunities.
The company also highlighted its progress in telesurgery, having completed 175 telesurgeries as of June 30, including a landmark procedure spanning more than 13,600 miles between Colombia and India. This achievement underscores the system's capability to enable remote surgical procedures, which could revolutionize access to surgical care in underserved regions.
SS Innovations' financial position remains solid, with $13.6 million in cash and cash equivalents and no long-term debt as of June 30. The company's focus on making robotic surgery affordable and accessible aligns with a growing global demand for minimally invasive surgical options, particularly in emerging markets.
The record revenue and installation numbers reflect the company's successful execution of its commercialization strategy, which is centered on the SSi Mantra's cost-effectiveness and user-friendly design. As the company prepares for potential FDA clearance and CE marking, its expanding installed base and procedure volume will be key indicators of its ability to capitalize on these regulatory milestones.
Investors and industry observers will be watching closely to see if SS Innovations can sustain this momentum and translate its growing adoption into profitability. The company's performance in the coming quarters will be crucial in determining its trajectory in the competitive surgical robotics market.
For more information about SS Innovations, visit the company's newsroom at https://ibn.fm/SSII.
